Spider Venom Drug Enters Human Trials to Protect Heart and Brain

A groundbreaking drug derived from Australian funnel-web spider venom has entered human trials. Called IB409, the treatment aims to shield the heart and brain during life-threatening events like heart attacks and strokes. Currently, no approved drugs exist to protect these organs in such emergencies.

Researchers at the University of Queensland have begun testing its safety in healthy volunteers, marking the start of a multi-year clinical programme.

The drug's origins trace back to a molecule found in the venom of a funnel-web spider native to K'gari, formerly known as Fraser Island. Preclinical studies of the protein Hi1a—on which IB409 is based—revealed striking potential in reducing damage to the heart and brain.

Phase one of the trial is now underway, focusing on safety, tolerability, and correct dosing in humans. If successful, the second phase will assess whether IB409 can effectively guard heart health during a heart attack. This stage is expected to conclude by mid-2026.

The full trial will span five to seven years. Following phase two, a larger phase three study involving around 1,000 patients across multiple centres will run from late 2026. Regulatory submissions to agencies like the FDA and EMA are planned for 2029, with a review period of 10 to 12 months. Funding for the project comes from federal government grants and donations from medical charities.

If approved, IB409 would likely be given by paramedics or doctors soon after a cardiac event. Early intervention could limit organ damage, improve survival rates, and ease long-term healthcare demands.

The trial represents a major step toward filling a critical gap in emergency medicine. With no existing treatments to protect the heart or brain during strokes or heart attacks, IB409's success could transform patient outcomes. The coming years will determine whether this venom-derived drug becomes a standard tool in saving lives.